

centers C₁, C₃, C₂₀ and C₂₄.

16. The compound of claim 3 with S stereochemistry at carbon centers C₁, C₃, C₂₀ and C₂₄.

17. The compound of claim 4 with S stereochemistry at carbon centers C₁, C₃, C₂₀ and C₂₄.

18. The compound of claim 5 with S stereochemistry at carbon centers C₁, C₃, C₂₀ and C₂₄.

19. The compound of claim 6 with S stereochemistry at carbon centers C₁, C₃, C₂₀ and C₂₄.

REMARKS

Examiner Interview

Applicants, their attorney, Dr. Richard Pariza and Dr. John Nelson would like to thank Examiner Badio for her time and courtesy in discussing the application during a telephone interview on April 19. The interview focused on the differences in the therapeutic/toxicological profile of 1 α -hydroxyvitamin D₃ compared to other vitamin D analogues which, Applicants contend, renders 1 α -hydroxyvitamin D₃ nonobvious.

Status of the Application

Claims 1-14 are pending. Claims 7-9 have been withdrawn from consideration as directed to a separate invention. Claims 1-6 and 10-14 stand rejected.

Election/Restriction

Applicants note that the election requirement has been deemed proper and is therefore made final.